ArticlePhenomics (Cham, Switzerland)2025
Identification of a Novel Pyroptosis-Related lncRNAs Prognosis Model and Subtypes in Ovarian Cancer.
Article in Phenomics (Cham, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Upregulation of the lncRNACells · 2026Article
- DMGAT: predicting ncRNA-drug resistance associations based on diffusion map and heterogeneous graph attention network.Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC), a predominant gynecological malignancy, has consistently showcased grim prognostic outcomes. This investigation delves into the emerging field of pyroptosis and the intricacies of long non-coding RNAs (lncRNAs), specifically the lesser-studied pyroptosis-related lncRNAs (PRlncRNAs), and their roles in OC prognosis. By harnessing transcriptome, and clinic data from the genotype-tissue expression (GTEx) and the cancer genome Atlas (TCGA), we formulated a unique PRlncRNAs risk model consisting of five prognostic lncRNAs by Cox regression and least absolute shrinkage and selection operator (LASSO) regression. Next, the Kaplan-Meier analysis, receiver operating characteristic (ROC) curve, nomogram, and calibration were implemented to verify and evaluate the model. The model also showed general applicability in pan-cancer analysis. Remarkably, our model, upon rigorous validation, outperformed 16 pre-existing counterparts, offering a promising avenue for prognosis prediction. The risk score was used to classify patients into high and low-risk subgroups. The low-risk group showed improved overall survival (OS) and progression-free survival (PFS). The risk score was proved to be an independent prognosis factor. The low-risk group patients also exhibited a higher immune infiltration score and homologous recombination deficiency (HRD) score. Moreover, consensus clustering analysis was utilized to categorize OC patients into three distinct groups, predicated on the expression of the five prognostic lncRNAs. Patients within the third cluster exhibited noteworthy traits, encompassing elevated survival, heightened immune checkpoint expression, and the HRD score. Finally, the expressions of five PRlncRNAs were validated by quantitative real-time PCR (qRT-PCR) in OC cell lines and tissues. In conclusion, the risk model based on the five PRlncRNAs might function as prognostic biomarkers to predict the immune and target drug treatment in OC. Supplementary Information: The online version contains supplementary material available at 10.1007/s43657-024-00173-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.